(OCSL) Oaktree Specialty Lending - Overview
Stock: Debt, Equity, Mezzanine, Senior, Junior
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 12.24% |
| Yield on Cost 5y | 16.49% |
| Yield CAGR 5y | 32.40% |
| Payout Consistency | 90.1% |
| Payout Ratio | 103.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 28.1% |
| Relative Tail Risk | 7.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.60 |
| Alpha | -24.64 |
| Character TTM | |
|---|---|
| Beta | 0.626 |
| Beta Downside | 0.715 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.78% |
| CAGR/Max DD | -0.15 |
Description: OCSL Oaktree Specialty Lending January 19, 2026
Oaktree Specialty Lending Corp. (NASDAQ:OCSL) is a Business Development Company that targets middle-market companies in North America, providing bridge, first- and second-lien, mezzanine, and senior debt financing ranging from $5 million to $75 million, often with an equity co-investment component. The fund focuses on firms with enterprise values of $20 million–$150 million and EBITDA of $3 million–$50 million, and it aims to act as the lead investor across sectors such as education, business services, healthcare, manufacturing, technology, and consumer retail.
As of the latest 10-K, OCSL reported a net asset value (NAV) of roughly $1.1 billion and a weighted-average portfolio yield of 9.2%, reflecting its emphasis on higher-yielding, senior-secured credit. The fund’s performance is sensitive to the U.S. interest-rate cycle; a flattening yield curve typically tightens middle-market credit spreads, enhancing OCSL’s spread-over-LIBOR earnings. Additionally, robust M&A activity in the healthcare and technology sectors-driven by aging demographics and digital transformation-provides a steady pipeline of sponsor-led acquisition opportunities that align with OCSL’s investment mandate.
For a deeper, data-driven look at OCSL’s risk-adjusted returns and sector exposure, you may find ValueRay’s analytics platform useful.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 32.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.69 > 1.0 |
| NWC/Revenue: -19.06% < 20% (prev 112.9%; Δ -131.9% < -1%) |
| CFO/TA 0.03 > 3% & CFO 79.4m > Net Income 32.3m |
| Net Debt (1.59b) to EBITDA (85.9m): 18.52 < 3 |
| Current Ratio: 0.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.1m) vs 12m ago 7.10% < -2% |
| Gross Margin: 62.22% > 18% (prev 0.28%; Δ 6194 % > 0.5%) |
| Asset Turnover: 6.99% > 50% (prev 5.70%; Δ 1.29% > 0%) |
| Interest Coverage Ratio: 0.77 > 6 (EBITDA TTM 85.9m / Interest Expense TTM 111.9m) |
Altman Z'' -1.44
| A: -0.01 (Total Current Assets 104.7m - Total Current Liabilities 145.9m) / Total Assets 3.10b |
| B: -0.30 (Retained Earnings -914.8m / Total Assets 3.10b) |
| C: 0.03 (EBIT TTM 85.9m / Avg Total Assets 3.09b) |
| D: -0.55 (Book Value of Equity -913.9m / Total Liabilities 1.66b) |
| Altman-Z'' Score: -1.44 = CCC |
What is the price of OCSL shares?
Over the past week, the price has changed by -0.82%, over one month by -5.89%, over three months by -7.76% and over the past year by -11.58%.
Is OCSL a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OCSL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.4 | 10.6% |
| Analysts Target Price | 13.4 | 10.6% |
| ValueRay Target Price | 13.4 | 10.6% |
OCSL Fundamental Data Overview February 09, 2026
P/E Forward = 8.3126
P/S = 3.5032
P/B = 0.7443
P/EG = 0.9343
Revenue TTM = 216.1m USD
EBIT TTM = 85.9m USD
EBITDA TTM = 85.9m USD
Long Term Debt = 1.51b USD (estimated: total debt 1.61b - short term 98.4m)
Short Term Debt = 98.4m USD (from shortTermDebt, last quarter)
Debt = 1.61b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.59b USD (from netDebt column, last quarter)
Enterprise Value = 2.60b USD (1.07b + Debt 1.61b - CCE 80.8m)
Interest Coverage Ratio = 0.77 (Ebit TTM 85.9m / Interest Expense TTM 111.9m)
EV/FCF = 32.74x (Enterprise Value 2.60b / FCF TTM 79.4m)
FCF Yield = 3.05% (FCF TTM 79.4m / Enterprise Value 2.60b)
FCF Margin = 36.72% (FCF TTM 79.4m / Revenue TTM 216.1m)
Net Margin = 14.94% (Net Income TTM 32.3m / Revenue TTM 216.1m)
Gross Margin = 62.22% ((Revenue TTM 216.1m - Cost of Revenue TTM 81.7m) / Revenue TTM)
Gross Margin QoQ = 87.83% (prev 84.43%)
Tobins Q-Ratio = 0.84 (Enterprise Value 2.60b / Total Assets 3.10b)
Interest Expense / Debt = 1.66% (Interest Expense 26.7m / Debt 1.61b)
Taxrate = 0.64% (36.0k / 5.64m)
NOPAT = 85.3m (EBIT 85.9m * (1 - 0.64%))
Current Ratio = 0.72 (Total Current Assets 104.7m / Total Current Liabilities 145.9m)
Debt / Equity = 1.12 (Debt 1.61b / totalStockholderEquity, last quarter 1.44b)
Debt / EBITDA = 18.52 (Net Debt 1.59b / EBITDA 85.9m)
Debt / FCF = 20.04 (Net Debt 1.59b / FCF TTM 79.4m)
Total Stockholder Equity = 1.46b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.04% (Net Income 32.3m / Total Assets 3.10b)
RoE = 2.21% (Net Income TTM 32.3m / Total Stockholder Equity 1.46b)
RoCE = 2.89% (EBIT 85.9m / Capital Employed (Equity 1.46b + L.T.Debt 1.51b))
RoIC = 2.88% (NOPAT 85.3m / Invested Capital 2.96b)
WACC = 4.27% (E(1.07b)/V(2.68b) * Re(8.22%) + D(1.61b)/V(2.68b) * Rd(1.66%) * (1-Tc(0.01)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.38%
[DCF Debug] Terminal Value 82.51% ; FCFF base≈112.4m ; Y1≈82.2m ; Y5≈46.5m
Fair Price DCF = N/A (negative equity: EV 1.45b - Net Debt 1.59b = -139.9m; debt exceeds intrinsic value)
EPS Correlation: -68.74 | EPS CAGR: -7.08% | SUE: 1.02 | # QB: 1
Revenue Correlation: 17.11 | Revenue CAGR: 33.84% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.37 | Chg30d=-0.007 | Revisions Net=+1 | Analysts=7
EPS current Year (2026-09-30): EPS=1.52 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=-13.8% | Growth Revenue=-5.5%
EPS next Year (2027-09-30): EPS=1.47 | Chg30d=-0.052 | Revisions Net=-3 | Growth EPS=-3.5% | Growth Revenue=-0.7%